Study Highlights Experiences of Patients Treated with ADV7103 for Distal Renal Tubular Acidosis
source: pixabay.com

Study Highlights Experiences of Patients Treated with ADV7103 for Distal Renal Tubular Acidosis

According to a recent article, a new study is demonstrating how the effects of distal renal tubular acidosis impact a patient’s quality of life. Distal Renal Tubular Acidosis (dRTA) Distal…

Continue Reading Study Highlights Experiences of Patients Treated with ADV7103 for Distal Renal Tubular Acidosis
EC Approves ADV7103 Marketing Authorization for dRTA
source: pixabay.com

EC Approves ADV7103 Marketing Authorization for dRTA

Recently, the European Commission (EC) approved a marketing authorization for ADV7103 (Sibnayal), the first approved treatment for patients with distal renal tubular acidosis (dRTA). In a news release, pharmaceutical company…

Continue Reading EC Approves ADV7103 Marketing Authorization for dRTA